Clinical Trial Update: Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) [Phase 3]

View source ↗

Summary

A Phase 3 trial of extended-release niacin added on with laropiprant for dyslipidemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Extended-release Niacin (Niacin (extended-release))
• Laropiprant (laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 3 | Status: WITHDRAWN